CompletedNCT02933606RESTOREUpdated Feb 27, 2023Results posted

Phase II Study of BNC210 in PTSD

A Phase 2 interventional study of BNC210 and Placebo in Post-Traumatic Stress Disorder, sponsored by Bionomics Limited. Completed at 25 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-27.

Sponsored by Bionomics Limited · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 193
Allocation: Randomized
Ages: 18 Years to 70 Years
Sex: All

Study summary

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Conditions studied

Post-Traumatic Stress Disorder

Browse trials for

In context

Stress Disorders, Traumatic

1,147 studies on the registry are indexed under Stress Disorders, Traumatic; 108 are open to participants now.

This study's enrollment of 193 is above the median of 60 across 908 interventional studies indexed under Stress Disorders, Traumatic.

Browse Stress Disorders, Traumatic studies →

Lead sponsor

Bionomics Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 70 Years
Sexes eligible: All
Accepts healthy volunteers: No

Eligibility criteria

Key Inclusion Criteria:

Signed and dated informed consent.
Male or female between 18 and 70 years of age, inclusive.
Diagnosed with current PTSD as defined by the CAPS-5 for DSM-5.
Currently not using any psychiatric medications except for:
- No more than one selective serotonin reuptake inhibitor (SSRI) (fluvoxamine is excluded) or serotonin noradrenaline reuptake inhibitor (SNRI) within the licensed prescribing dose range. Subjects must have been on a stable dose for at least 3 months prior and through Screening, with the intent to remain on the same dose through to Week 16.
- As needed (PRN) use of benzodiazepines (BZD) at a frequency not exceeding 2 days per week in the 3 months prior to Screening. The total dose must not exceed 30 mg/day in diazepam equivalents.
Subjects not currently receiving psychotherapy except long term supportive counseling or subjects that have received intensive regular psychotherapy for a minimum of three months prior to Screening.
Females of childbearing potential must have a negative serum pregnancy. Females not of childbearing potential must be postmenopausal. Sterilized male patients must be at least 1 year post-vasectomy to be considered of non-child bearing potential. Females and males of childbearing potential must agree to use two effective methods of contraception.

Key Exclusion Criteria

Current and ongoing exposure to the trauma that caused the PTSD.
Failed more than three trials of antidepressant medication(s) prescribed for the treatment of PTSD. Each trial must have lasted at least 6 weeks to be considered a failed attempt. A trial that was terminated due to intolerability or side effects does not constitute a failed attempt.
The use of psychiatric medications within 2 weeks of Screening except for SSRIs, SNRIs or limited PRN BZD use as per inclusion criterion 4. Restricted psychiatric medications include (but are not limited to) antidepressants not allowed by inclusion criterion 4, antianxiety drugs (except limited BZD use per inclusion criterion 4), mood stabilizers, stimulants, antipsychotics, hypnotics and acetylcholinesterase inhibitors.
History of significant traumatic brain injury.
Depression as measured by Montgomery-Äsberg depression scale (MADRS) rating > 23.
Bipolar and psychotic disorders as identified at Screening using the MINI International Neuropsychiatry Interview (V7.0) (M.I.N.I).
A score ≥ 7 on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) at Screening.
History of seizure disorders, uncontrolled sleep apnoea or severe neurologic disease.
Increased risk of suicide, defined as:
- Any previous suicide attempt disclosed by the participant at Screening using the Columbia Suicide Severity Rating Scale (C-SSRS).
- Any suicidal ideation with intent (yes to item 4 and / or 5) or suicidal behavior in the past year, as captured at Screening using the C-SSRS.
- A score > 4 on item 10 of the MADRS at Screening.
The use of alprazolam or flunitrazepam within 3 months of Screening.
Any clinically significant abnormalities in laboratory test results, vitals signs, or ECG at Screening.
Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) at Screening.
Any moderate to severe substance use disorder (any type) in the 12 months prior to Screening as identified by the DSM-5 using the M.I.N.I (V7.0).
Current Australian serving Defense personnel or any member of the US military currently serving on active duty.
Participants involved with ongoing insurance or workplace claims that in the opinion of the Investigator are likely to have an impact on the mental health, presentation or capacity of the patient to engage in the study.

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 193 participants (actual)

Study arms

Experimental
BNC210 600 mg b.i.d.
Suspension administered orally for 12 weeks.
Drug: BNC210
Experimental
BNC210 300 mg b.i.d.
Suspension administered orally for 12 weeks.
Drug: BNC210
Experimental
BNC210 150 mg b.i.d.
Suspension administered orally for 12 weeks.
Drug: BNC210
Placebo comparator
Placebo b.i.d.
Suspension administered orally for 12 weeks.
Drug: Placebo

Interventions

DrugBNC210
DrugPlacebo

What researchers measure

Primary outcomes

Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score
Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.

Secondary outcomes

Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).
Self-reported PTSD symptom severity. The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.
Montgomery- Åsberg Depression Rating Scale (MADRS).
Depression severity. The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.
Hamilton Anxiety Rating Scale (HAM-A).
Anxiety severity. The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks
Clinical Global Impressions - Severity Scale (CGI-S).
Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S).
Time frame: 12 weeks
Clinical Global Impressions - Improvement Scale (CGI-I).
Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I).
Time frame: 12 weeks
Patient Global Impressions - Severity Scale (PGI-S).
Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S).
Time frame: 12 weeks.
Patient Global Impression - Improvement Scale (PGI-I).
Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I).
Time frame: 12 weeks.
Assessment of Quality of Life (AQoL-8D).
Quality of Life. The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life.
Time frame: 12 weeks.
Social Functioning: Sheehan Disability Scale (SDS).
Social functioning. The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment.
Time frame: 12 weeks.
Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).
Sleep quality and duration. The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality
Time frame: 12 weeks.
CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment
The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better) A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean
Time frame: 12 Weeks

Results

Posted Feb 27, 2023

Limitations and caveats

BNC210 suspension that is dependent on concomitant food intake did not achieve expected exposure levels in the trial participants. However, a planned pharmacometrics analysis established a model of CAPS-5 scores versus plasma exposure and predicted a target exposure for future trials (O'Connor S., SOBP Conference Poster, 2019). A new tablet formulation is being evaluated in a second BNC210 Phase 2 PTSD trial (NCT04951076) and substantially higher exposures are expected in the participants.

Participant flow

Participant flow — Overall Study
Milestone	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Started	49	48	47	49
Completed	33	39	33	30
Not completed	16	9	14	19

Outcome measures

PrimaryClinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score

Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score	15.26 (11.2 to 19.3)	16.62 (12.3 to 20.9)	19.76 (15.5 to 24.0)	14.57 (9.8 to 19.4)

SecondaryPost-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).

Self-reported PTSD symptom severity. The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).	25.02 (19.1 to 31.0)	20.99 (15.3 to 26.7)	29.97 (23.5 to 36.4)	24.65 (17.8 to 31.5)

SecondaryMontgomery- Åsberg Depression Rating Scale (MADRS).

Depression severity. The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease.

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Montgomery- Åsberg Depression Rating Scale (MADRS).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Montgomery- Åsberg Depression Rating Scale (MADRS).	9.48 (6.7 to 12.3)	10.25 (7.7 to 12.8)	12.16 (9.4 to 14.9)	8.94 (6.1 to 11.8)

SecondaryHamilton Anxiety Rating Scale (HAM-A).

Anxiety severity. The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease.

Time frame:: 12 weeks
Reported as:: Least squares mean · score on a scale

Hamilton Anxiety Rating Scale (HAM-A).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Hamilton Anxiety Rating Scale (HAM-A).	9.03 (6.6 to 11.5)	9.94 (7.6 to 12.3)	10.55 (8.1 to 13.0)	7.94 (5.3 to 10.6)

SecondaryClinical Global Impressions - Severity Scale (CGI-S).

Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S).

Time frame:: 12 weeks
Reported as:: Count of participants · Participants

Clinical Global Impressions - Severity Scale (CGI-S).
Participants	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Normal, not at all ill	10	5	5	10
Borderline mentally ill	5	3	6	6
Mildly ill	8	16	8	5
Moderately ill	9	13	9	7
Markedly ill	1	2	3	1
Severely ill	0	0	2	1
Among the most extremely ill patients	0	0	0	0

SecondaryClinical Global Impressions - Improvement Scale (CGI-I).

Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I).

Time frame:: 12 weeks
Reported as:: Count of participants · Participants

Clinical Global Impressions - Improvement Scale (CGI-I).
Participants	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Very Much Improved/Much Improved	22	23	15	19
Other	11	16	18	11

SecondaryPatient Global Impressions - Severity Scale (PGI-S).

Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S).

Time frame:: 12 weeks.
Reported as:: Count of participants · Participants

Patient Global Impressions - Severity Scale (PGI-S).
Participants	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Normal	11	6	6	10
Mild	8	21	14	13
Moderate	12	11	9	3
Severe	2	1	4	4

SecondaryPatient Global Impression - Improvement Scale (PGI-I).

Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I).

Time frame:: 12 weeks.
Reported as:: Count of participants · Participants

Patient Global Impression - Improvement Scale (PGI-I).
Participants	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Very Much/Much Improved	17	20	18	20
Other	16	19	15	10

SecondaryAssessment of Quality of Life (AQoL-8D).

Quality of Life. The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life.

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Assessment of Quality of Life (AQoL-8D).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Assessment of Quality of Life (AQoL-8D).	77.95 (71.4 to 84.5)	76.79 (70.3 to 83.3)	85.47 (78.0 to 93.0)	81.05 (73.3 to 88.9)

SecondarySocial Functioning: Sheehan Disability Scale (SDS).

Social functioning. The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment.

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Social Functioning: Sheehan Disability Scale (SDS).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Social Functioning: Sheehan Disability Scale (SDS).	8.84 (6.2 to 11.5)	6.66 (4.0 to 9.3)	10.32 (7.5 to 13.1)	8.47 (5.3 to 11.7)

SecondarySleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).

Sleep quality and duration. The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality

Time frame:: 12 weeks.
Reported as:: Least squares mean · score on a scale

Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).
score on a scale	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).	8.80 (7.5 to 10.1)	8.83 (7.6 to 10.1)	9.15 (7.7 to 10.6)	8.00 (6.4 to 9.6)

SecondaryCANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment

The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better) A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean

Time frame:: 12 Weeks
Reported as:: Least squares mean · Composite Z score

CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment
Composite Z score	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment	0.06 (-0.1 to 0.2)	0.12 (0.0 to 0.2)	0.18 (0.1 to 0.3)	0.02 (-0.1 to 0.2)

Adverse events

Collected over 15 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
BNC210 600 mg b.i.d.	0/48 (0%)	0/48 (0%)	31/48 (64.6%)
BNC210 300 mg b.i.d.	0/48 (0%)	1/48 (2.1%)	42/48 (87.5%)
BNC210 150 mg b.i.d.	0/47 (0%)	0/47 (0%)	30/47 (63.8%)
Placebo b.i.d.	0/49 (0%)	1/49 (2%)	45/49 (91.8%)

Most frequent serious events

Most frequent serious events
Event	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
Elevated Liver Function TestsInvestigations	0/48	1/48	0/47	0/49
Acute AbdomenGastrointestinal disorders	0/48	0/48	0/47	1/49

Most frequent other events

Showing 10 of 13

Most frequent other events
Event	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.
HeadacheNervous system disorders	3/48	10/48	4/47	12/49
Upper Respiratory Tract InfectionInfections and infestations	4/48	3/48	6/47	2/49
DiarrhoeaGastrointestinal disorders	4/48	6/48	4/47	6/49
NauseaGastrointestinal disorders	4/48	4/48	2/47	6/49
FatigueGeneral disorders	2/48	5/48	2/47	1/49
NasopharyngitisInfections and infestations	4/48	2/48	1/47	1/49
DizzinessNervous system disorders	2/48	3/48	1/47	4/49
Dry MouthGastrointestinal disorders	3/48	0/48	3/47	3/49
SomnolenceNervous system disorders	3/48	3/48	2/47	1/49
Viral InfectionInfections and infestations	1/48	3/48	2/47	0/49

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.	Total
<=18 years	1	0	1	0	2
Between 18 and 65 years	46	48	46	49	189
>=65 years	1	0	0	0	1

Sex: Female, Male
Sex: Female, Male(Participants)	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.	Total
Female	25	26	31	30	112
Male	23	22	16	19	80

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.	Total
American Indian or Alaska Native	0	0	0	0	0
Asian	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	1	1	2
Black or African American	16	11	8	10	45
White	30	35	36	34	135
More than one race	1	1	2	3	7
Unknown or Not Reported	1	1	0	1	3

Region of Enrollment
Region of Enrollment(participants)	BNC210 600 mg b.i.d.	BNC210 300 mg b.i.d.	BNC210 150 mg b.i.d.	Placebo b.i.d.	Total
United States	41	41	41	38	161
Australia	7	7	6	11	31

Study locations

25 sites

Oceanside, California 92056, United States
Rancho Mirage, California 92270, United States
Redlands, California 92374, United States
Riverside, California 92506, United States
Gainesville, Florida 32607, United States
Jacksonville, Florida 32256, United States
Lauderhill, Florida 33309, United States
North Miami, Florida 33161, United States
Oakland Park, Florida 33334, United States
Orlando, Florida 32801, United States
Hoffman Estates, Illinois 60169, United States
Overland Park, Kansas 66211, United States
New Bedford, Massachusetts 02740, United States
Lincoln, Nebraska 68526, United States
Las Vegas, Nevada 89102, United States
Berlin, New Jersey 08009, United States
Canton, Ohio 44718, United States
Memphis, Tennessee 38119, United States
Dallas, Texas 75231, United States
San Antonio, Texas 78229, United States
Penrith, New South Wales 2751, Australia
Auchenflower, Queensland 4066, Australia
Toowong, Queensland 4066, Australia
Elizabeth Vale, South Australia 5112, Australia
St Kilda, Victoria 3004, Australia

References and documents

Study documents

Study protocol · May 30, 2018
Statistical analysis plan · Sep 27, 2018

Documents are hosted by the registry — open the source record to download them.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02933606
Lead sponsor: Bionomics Limited
Responsible party: Sponsor
First posted: Oct 14, 2016
Start date: Jun 30, 2016
Primary completion: Jul 5, 2018
Completion: Jul 25, 2018
Results posted: Feb 27, 2023
Last update: Feb 27, 2023

Oversight

FDA-regulated drug: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stress Disorders, Traumatic→

Other studies from this sponsor

Bionomics Limited

Start the discussion